{"name":"Kexing Biopharm Co., Ltd.","slug":"kexing-biopharm-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Human interferon α1b Inhalation Solution","genericName":"Human interferon α1b Inhalation Solution","slug":"human-interferon-1b-inhalation-solution","indication":"Viral respiratory infections (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"Human interferon α1b Inhalation Solution","genericName":"Human interferon α1b Inhalation Solution","slug":"human-interferon-1b-inhalation-solution","phase":"phase_3","mechanism":"Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity.","indications":["Viral respiratory infections (Phase 3 development)","COVID-19 (potential indication under investigation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0IyRmpWZzhoSnhlMVFEdVdtRzM2TjRtN0FfSXp5YjBSMHJVcGZwNlJxR09OODhWQWhIM3NRcV9pdEczQUhiaEs1aXpXYVlRWFlWb1k5QVVfd0t5bmQxRmVGblpDZVM4SmRtN2taaExmRU9KN3BmLU95bVRRM1V4aWtYaEZQVGpZNzRsOEVrSTdVc2FiVTFDcDJhb19DczA5M2IzM0FR?oc=5","date":"2025-12-09","type":"pipeline","source":"BioWorld News","summary":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025 - BioWorld News","headline":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNNWhUNjZGN2FoUUVzTTR4TWZwTXY1TEF2dXVaMy1WaFQ2UEVXaWNUd1NoNHM5aTNUZVJpclJRT0xsaHNyaWYwX0YzaTlhM2JMQ1d2M0RIZExLRkkyTDJmbUZ6SXp5UVpzeGpuYlp4RHczQ05scDV4YWRWN19rSGdfZEc1cWp6ZXhwMEI4Mm9FUElQZUV2UmFiNEJ6dmtZTWtxempjY1c4LVhiUVVIdVNIVENOVW8yLUoxd0dKVjFIOGlYRlRWcGxZdEln?oc=5","date":"2025-10-27","type":"pipeline","source":"PR Newswire","summary":"BioDlink Completes First International Shipment of Bevacizumab to Colombia - PR Newswire","headline":"BioDlink Completes First International Shipment of Bevacizumab to Colombia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLXBiSWhQb3FPNHlfRUlYejBhYlpTOU1Hb2FsckpkVjBBQkU2RkUwN2FtLVRyNE1COExWYlYySkd1dHFudzJOSkppSjlHZS1WRHJCX3JhWTFHcUJtczBJWERPRWR0RE1DVFMzUHNwQzdWNXlCNHMwS04yWWItQkU3Q0VTZmNpVjhtX2owbjlRbnZaMzh3aS12cUNIRGRrM1d5Xy1DaGl3TFFncHc?oc=5","date":"2025-10-16","type":"pipeline","source":"The Pharma Letter","summary":"Xuanzhu Bio raises $100 million in oversubscribed Hong Kong IPO - The Pharma Letter","headline":"Xuanzhu Bio raises $100 million in oversubscribed Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-02","type":"pipeline","source":"simplywall.st","summary":"IQVIA Holdings (IQV) Announces CFO Transition With Michael Fedock Succeeding Ron Bruehlman - simplywall.st","headline":"IQVIA Holdings (IQV) Announces CFO Transition With Michael Fedock Succeeding Ron Bruehlman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPcUVqbUFEZDZHRXVURkV1UFlkZG9YWTVtQU1ja2JLbjlTTklpOFRDWnF1UWJEMW40NnNPYWJJeFNiVkJhYThtZUVWMTMxbkFqQ3R0U3A5b0R4Mmp5eTBjb3R3NERubkREVUVHRlpfZFZVRWdZRzFEZmNBNVRteHFVZk9xNlpBV1QtdHBvaDZRbGd1d29xRGgxTWw3bERydmw2ZHF4RFpRNHZJcWdWajY0dkF6cUNkVm9JUnc?oc=5","date":"2025-08-13","type":"pipeline","source":"BioSpectrum Asia","summary":"Kexing Biopharm teams up with IQVIA to accelerate global expansion - BioSpectrum Asia","headline":"Kexing Biopharm teams up with IQVIA to accelerate global expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPOXVvTVhGeFdZLXRGQ1dqOFFjeTdYLUtBSWZGdlRaRllwS0ZJMVF0c205c3FBaWZCWjNtRUFHaXBIZDBiQm12QzcyeC0yTjNxcFVmYWpnUThrSUNjeHNZQ3l0THpyWk5OcEtBUUNkeUoyOW1mOTdYZVc2eXl4dlNGNXRWckFhRHhTZHhxOE1obGVJNHR1OXJrUnkzNEYybEFvOTZpNDFGU3FtVWtnVDhTR2I2Yy1uM3htaVFaX1NId2h2SV9nRXY1Ny0xNl9pdEk4V1RlUnU2WVM4dw?oc=5","date":"2025-08-13","type":"pipeline","source":"PR Newswire","summary":"BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan - PR Newswire","headline":"BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQZ3lqWUtxTmhjMUdHUU1Rb3h2WVpyWmxSRFZTT3pLZVZ4Yndaa3U0TktsSUxoa3VhTWtEcEtqNFZKYjBCcmhaRW14TEc4ZjlVRng5THhjQnRBM0hXM2h4dzIzRjljelBnYVdzajRubnh0U1g5YVQyM3NlYmpLSE5Ecm1tWUljR3Y5SGltR0llRDdFWmRBbHFJN1JQWVg2MmhSVzJxbTMzby1uR0xlRldIanlnYmhKTlBZOVdnRWlLNFdkMEJaenc?oc=5","date":"2025-06-05","type":"pipeline","source":"PR Newswire","summary":"BioDlink Strengthens Global Compliance with Argentina GMP Certification - PR Newswire","headline":"BioDlink Strengthens Global Compliance with Argentina GMP Certification","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPTnYwaHFpNEtXVk1TWlA5c0JZZ01VMmstYnFOdC1JYmJnUTg5TnpYRUpLTktrYllXUnA2ck8wYm5XZy01RUVfYjJRTklnV3VKMDBUWmV6MmhUMUFsZnh2T1B5Z3lqRUlwWVlIODhrSmQyUk5TWkVETGlzc0tIVlgwXzNYUmYzbkM1OUtZZndxQjBlWllWS0QtY3I5VC05X2RETWVXTHN5MVBRLUhKdVZGMjBIQUt2UGdFWGxLYm9UdFAxM29NVHRJ?oc=5","date":"2025-05-21","type":"pipeline","source":"PR Newswire","summary":"BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth - PR Newswire","headline":"BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQeDg5RGVGRWM3dy1hV1JCNGt5b0hsZGt0NGMyRmFfYzYzWHZXektGSDdlekRVZXlyU3NUbjYyRlhwZUg2R2JMTlhuTk1DTmI0b19hZkR3YldoTkMzWGlsV1BhUXlrUkRoVmRrc0RFYmNkT2ZSam92QlkzUks2YnJXaVhiWERTM29Qb3d0eDFCbzhQRmRQbmhIYWREVHVBOFM4azRSa2NLSEc2YjRIMXlWS3RmeG5ncEZrdEtWSEZmT0pFaXc5bG5SR0JPcw?oc=5","date":"2024-07-31","type":"regulatory","source":"BioSpectrum Asia","summary":"Chinese generic drug for breast, pancreatic, and lung cancer approved in EU market - BioSpectrum Asia","headline":"Chinese generic drug for breast, pancreatic, and lung cancer approved in EU market","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxORFZOZ1pCT3dLUUJ2N3VrYk4tRE9NM0lzdGJ5bHZUWmh4TkhkbDl1VDVuOUt0QXVRbzYtdGNycHhHa0ZKYklnOTJ2aC01N2tCSW9oNXpKRDh1OWVTMHZUMUw0d0QwLW5WZGtiS19XeHlQSl9rRVJENGV3UmFQVkctYjZaM3ZXMVZkZ1hRZTI5eEpfQjVuS3Rid2NEejlnZWlZQUF6VktEbnFHbGk2RGZQSVpXYWVnclBkdmp3bFFsM3BYZw?oc=5","date":"2021-11-10","type":"deal","source":"Contract Pharma","summary":"Biosynth Carbosynth & Shengquan Acquire Factory from Kexing Biopharmaceutical - Contract Pharma","headline":"Biosynth Carbosynth & Shengquan Acquire Factory from Kexing Biopharmaceutical","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}